| Date | Title | Description |
| 05.03.2026 | ImmunoScape Signs Clinical Trial MOU With U.S. Cancer Center And Secures Strategic Investment From Leonardo DiCaprio | ImmunoScape, a Singapore-headquartered biotechnology company developing next-generation T cell receptor (TCR) based cancer immunotherapies, announced that it has signed a memorandum of understanding with a leading National Cancer Institute-... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 23.02.2026 | Gilead Sciences Acquires Arcellx, for $7.8 Billion | Gilead Sciences, Inc. (Nasdaq: GILD), a Foster City, California-based provider of biopharmaceutical medicines for life-threatening diseases, acquired Arcellxi (NASDAQ:ACLX) , a Redwood City, California-based provider of innovative immunothe... |
| 17.02.2026 | Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity | Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers—Delivering Risk Prediction Where Proteomics Falls Short
MORRISVILLE, N.C., Feb. 17, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomic... |
| 10.01.2026 | UPenn, BioNTech, And Osage University Partners Launch $50 Million Seed Fund To Back Penn Life Science Startups | The University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a dedicated venture fund focused on early-stage life scienc... |
| 08.11.2025 | Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies | Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo... |
| 07.11.2025 | Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein Therapies | Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish... |
| 31.03.2025 | Epicrispr Biotechnologies: A New Dawn in Genetic Therapy | Epicrispr Biotechnologies is making waves in the biotechnology sector. The company recently secured $68 million in Series B funding. This financial boost is a beacon of hope for patients suffering from facioscapulohumeral muscular dystrophy... |
| 27.03.2025 | Henlius and Fosun Pharma: Navigating the Future of Healthcare Innovation | In the bustling landscape of global healthcare, two Chinese pharmaceutical giants, Henlius and Fosun Pharma, are carving their paths with innovation and strategic growth. Their recent annual results paint a vivid picture of resilience and a... |
| 26.03.2025 | Fosun Pharma Announces 2024 Annual Results | Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
SHANGHAI, March 26, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the G... |
| 26.03.2025 | Epicrispr Biotechnologies Raises $68M in Series B Funding | Epicrispr Biotechnologies, a South San Francisco, CA-based biotechnology company focused on developing curative therapies, raised $68m in the first close of its Series B financing.
The round was led by Ally Bridge Group, with participation ... |
| 04.12.2024 | Tomorrow's Promise, Today's Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment | From left to right, Candace S. Johnson, PhD, Cameron Nolan, Roswell Park nurse , and Michael Wong, MD, PhD, FRPC,
Roswell Park President and CEO Candace S. Johnson, PhD, today introduced the cancer center's first Physician in Chief — and th... |
| 30.10.2024 | Fosun Pharma Announces 2024Q3 Financial Results | Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion
Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer
SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Phar... |
| 28.10.2024 | Biotech Bootcamp: Launch Your Career in Frederick's Biotech Sector | Maryland MEP/RMI
Informational Session for the Next Biotech Bootcamp on November 1, 2024
FREDERICK, Md., Oct. 28, 2024 /PRNewswire-PRWeb/ --If you're looking to kickstart your career in the local biotech industry, Frederick's Biotech Bootca... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 11.06.2024 | SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit | SITC IO Drug Development Keynote Speaker
The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer I... |
| 05.06.2024 | Transforming LA into a Biotech Hub | Image Source: UCLA Health
Skeptics once doubted the feasibility of a high-speed rail connecting LA to Las Vegas, but now it's becoming a reality. Perhaps all it takes is the right team to turn the improbable into the possible.
LA County has... |
| 23.05.2024 | Biotech Bootcamp: Equipping the Future Workforce in the Life Sciences Industry | Biotech Boot Camp
Applications open for free day/evening biotech career training bootcamp in July
FREDERICK, Md., May 23, 2024 /PRNewswire-PRWeb/ -- For those interested in entry level employment within the local biotech industry, Frederick... |
| 21.12.2022 | Kite to Acquire Tmunity Therapeutics | Kite, a Santa Monica, CA-based Gilead Company (Nasdaq: GILD), acquired Tmunity Therapeutics, a Philadelphia, PA-based clinical-stage, private biotech company.
The amount of the deal was not disclosed. The transaction is expected to close in... |
| 06.01.2021 | Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors | Santa Monica, Calif.; Oxford, UK; and San Jose, Calif., January 6 2021 - Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-dr... |
| 15.12.2020 | Draper Signs Agreement with Kite to Accelerate Development of Cancer Immunotherapies | Draper signed an agreement with Kite, a Gilead Company, to accelerate development of cancer immunotherapies. Pictured is a device concept of Draper’s transduction system. Credit: Draper. “Over the next decade, cell and gene therapies are po... |
| 01.08.2019 | Kite Pharma founder’s venture capital firm closes new $600M fund | A Form D filed with the Securities and Exchange Commission on July 15 states that the firm had sought to raise $600 million. Another Form D, filed Dec. 6, 2017, states that Vida had raised $254.8 million.
“Vida maintains a unique advantage ... |
| 25.04.2019 | Kite Pharma to expand manufacturing capacity with Maryland plant | Kite’s pipeline page lists a single TCR product candidate, KITE-718, a MAGE A3/A6-targeting therapy in Phase I development. The trial page on ClinicalTrials.gov states that it the study, which started nearly two years ago, is designed to en... |
| 30.05.2018 | J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial | The CAR-T was originally developed by Nanjing, China-based Legend, under the development name LCAR-B38M. Janssen announced in December that it had paid Legend $350 million upfront for a worldwide licensing agreement for the therapy. The Chi... |
| 07.09.2017 | The inside story of how a $12 billion deal for a revolutionary cancer treatment came together | Reuters
Cancer cells are seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, March, 6, 2012.
One of the most attention-catching biotech deals of the year slotted into place after a fateful July m... |
| 30.08.2017 | A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved | Reuters
Cancer cells are seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, March, 6, 2012.
Advertisement
The US Food and Drug Administration (FDA) just approved a cutting-edge cancer therapy.
O... |
| 29.08.2017 | Here's why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment | jovan vitanovski/Shutterstock
For several years, investors of Gilead Sciences have clamored for the drug giant to jump back into the mergers-and-acquisitions game.
Advertisement
Since its bombshell hepatitis C treatments hit the market in 2... |
| 28.08.2017 | Gilead just bought a cancer immunotherapy company for $12 billion | Reuters
Cancer cells are seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, March, 6, 2012.
Gilead is acquiring cancer immunotherapy biotech Kite Pharma for $11.9 billion.
Advertisement
Gilead, ... |
| 28.08.2017 | Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsement | REUTERS/Suzanne Plunkett
A tray containing cancer cells sits on an optical microscope in the Nanomedicine Lab at UCL's School of Pharmacy in London.
Gilead is spending $12 billion to buy Kite Pharma, a biotech that has no approved therapies... |
| 28.08.2017 | Term Sheet — Monday, August 28 | DAY 1
Hi, I’m Polina Marinova, and it’s nice to formally meet you all. Although technically, we already know each other — for the past few months, I’ve been doing the deals section of Term Sheet. Literally started from the bottom (of this n... |
| 31.07.2017 | It’s not a competition but… Kite’s CAR-T therapy just claimed a first in Europe | The aim is to eventually treat 4-5,000 patients per year, starting with axi-cel, Kite CEO Arie Belldegrun told the conference crowd.
While the “race” to the market has received ample attention, most agree there is more than enough room for ... |
| 20.06.2017 | GE Ventures spin-out Vineti raises $13.75M for complex biomanufacturing | It’s problems like those that led to the creation of Vineti, a cloud-based software platform for advanced cell and gene therapies.
On Tuesday, the second day of the BIO International Convention in San Diego, the San Francisco, California-ba... |
| 29.03.2017 | First come, first served: Novartis finalizes CAR-T application, claims priority review | The equivalent approval application will be filed with the European Medicines Agency (EMA) later this year, the statement read.
Novartis has been at the front of the pack with its CAR-T program, acquired through a 2012 partnership with the ... |
| 28.02.2017 | Kite scores a landmark win with promising 6-month lymphoma data for lead CAR-T | Jeff Wiezorek, Kite
Kite Pharma’s closely-watched lead CAR-T turned in positive six-month results for aggressive non-Hodgkin lymphoma, hitting a key goal as the biotech rolls up to the FDA with its application for marketing ap... |
| 12.01.2017 | Jet-setting CAR-Ts: Kite details commercialization plans at #JPM17 | Chairman and CEO Arie Belldegrun said the company plans to finalize its BLA submission with the FDA in the first quarter of 2017. The equivalent filings in Europe would follow shortly after, paving the way for a global supply strategy.
“As ... |
| 08.12.2016 | Here’s 2017 biopharma sales projections, but Trump might have other plans | On Wednesday, Time Magazine’s ‘Person of the Year’ Donald Trump told the publication that he didn’t like where the market was heading.
“I’m going to bring down drug prices,” said President-Elect Trump, according to the interview transcript.... |
| 21.09.2016 | Cytokine storms force Mirna to shutter a trial; Artios gathers $33M for cancer drug work | Mirna CEO Paul Lammers
A series of severe cases of cytokine release syndrome forced Austin, TX-based Mirna Therapeutics to shut down a Phase I study of its lead microRNA drug, MRX34. Mirna also opted not to start another ... |
| 25.07.2016 | Kite grabs a stem cell biology ‘breakthrough’ in race for off-the-shelf T cell therapies | Looking for an edge in the race to develop blockbuster off-the-shelf cell therapies to fight cancer, Kite Therapeutics has grabbed a license for new T cell tech from UCLA that the biotech believes can play a breakthrough role i... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 19.03.2015 | West Coast Biotech Roundup: Juno, Nektar, Kite, Glooko & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Out west this week, Bay Area clinical data carried the day. Nektar got bad news from a Phase 3 breast cancer trial, but Pharmacyclics, about to become (a very expensive) part ... |
| 28.04.2014 | Kite Pharma Completes $50M Mezzanine Financing | Kite Pharma, Inc., a Santa Monica, CA-based clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, completed a $50m mezzanine private financing of co... |
| 28.04.2014 |
Kite Pharma Scores $50M For Cancer Immunotherapy
| Santa Monica-based Kite Pharma said this morning that it has raised $50M, in a mezzanine, private financing, made up of convertible notes. According to Kite Pharma, the funding came from an un-named syndicate of healthcare-dedicated investo... |
| 29.05.2013 | Biotech partnered with NCI rounds up $20M to advance cancer immunotherapies into the clinic | The process of removing T cells from a patient, genetically reprogramming them and re-injecting them into the patient has been FDA-approved and brought to market in the form of Provenge for prostate cancer and Yervoy for melanoma. Kite says... |
| 16.05.2013 | Kite Pharma Flys with $20M Investment |
LOS ANGELES, CA, Clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares.
>> Click here for more fundin... |
| 16.05.2013 | Kite Pharma Closes $20M Series A Funding; Converts $15M | Kite Pharma Inc., a Los Angeles, CA-based clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, closed a $20m in Series A funding.
In addition to these new funds, Kite converted $15m in n... |
| 15.05.2013 |
Kite Pharma Raises $35M
| - |
| 15.05.2013 | Kite Pharma Completes $35 Million Series A Preferred Stock Financing | - |
| 09.03.2012 | Kite Pharma Raises $15 Million in Initial Round | - |
| 09.03.2011 |
Kite Pharma Raises $15M
| Los Angeles-based Kite Pharma, a biopharmaceuticals firm developing treatments for cancer, said this morning that it has raised $15M in an initial round of funding. The funding was led by TPG Capital. As part of the funding, David Bonderman... |
| 09.03.2011 | Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors | - |
| 09.03.2011 | Kite Pharma Raises $15M Financing Round | Kite Pharma, Inc., a Los Angeles, CA-based biopharmaceutical company focused on developing innovative active immunotherapies for cancer, has raised $15m in an initial round of financing.
The round was led by TPG Capital.
The company intends... |
| - | Here’s 2017 biopharma sales projections, but Trump might have other plans | Now that we know who’s taking the White House, it’s a lot easier to predict the year ahead in biotech and pharma, EP Vantage writes in the foreword of its 2017 Preview report.
Or so we thought.
On Wednesday, Time Magazine’s ‘Person of the Y... |
| - | J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial | A Chinese CAR-T therapy that drew significant attention at last year’s American Society of Clinical Oncology meeting will enter a clinical trial in the US later this year.
Johnson & Johnson subsidiary Janssen said Wednesday that it had ... |
| - | GE Ventures spin-out Vineti raises $13.75M for complex biomanufacturing | For all the complexity of CAR-T autologous transplant technology, Vineti has a simple question to ask: What if the wrong cells are infused back into the patient?
That scenario is not as far-fetched as it sounds and it’s just one of many log... |
| - | Transforming LA into a Biotech Hub
🤝 Venture Deals
🤝 Venture Deals
📅 LA Tech Calendar
📙 What We’re Reading | Image Source: UCLA Health
Skeptics once doubted the feasibility of a high-speed rail connecting LA to Las Vegas, but now it's becoming a reality. Perhaps all it takes is the right team to turn the improbable into the possible.
LA County has... |
| - | Kite Pharma founder’s venture capital firm closes new $600M fund | A venture capital firm formed by a founder of one of the first companies to win Food and Drug Administration approval for a cell therapy for cancer closed a new fund worth more than half of $1 billion.
Boston-based Vida Ventures said Thursd... |
| - | 🚗 Toyota Launches H2HQ in Advanced Gardena
🤝 Venture Deals
🔦 Spotlight
🤝 Venture Deals
🤝 Venture Deals | 🔦 Spotlight
Image Source: Toyota
Toyota has transformed its facility in Gardena, CA, into a hydrogen research and development center to capitalize on the expanding market for hydrogen technology in California. With three decades of experien... |
| - | First come, first served: Novartis finalizes CAR-T application, claims priority review | Novartis has made good on its promise to submit a biologics license application (BLA) for its lead CAR-T candidate in the first quarter of the fiscal year. With two days to spare, no less.
According to a statement released on Wednesday, the... |
| - | Jet-setting CAR-Ts: Kite details commercialization plans at #JPM17 | CAR-T immunotherapy is one of the most resource-intensive and personalized therapies in clinical trials today. It can deliver astounding results, but the scalability and affordability of the therapy have always been in question.
As a joint ... |
| - | 🏰 Disney's Epic Investment Stands Out Amidst Gaming Industry Layoffs
🤝 Venture Deals
🤝 Venture Deals
📅 LA Tech Calendar
📙 What We’re Reading | 🔦 Spotlight
In the midst of widespread gaming industry layoffs, a glimmer of positive news emerges as Disney announces a significant move: a $1.5 billion investment in Epic Games. 🏰💰🐭
Image Source: Disney
Disney's $1.5 billion investment in... |
| - | It’s not a competition but… Kite’s CAR-T therapy just claimed a first in Europe | As Novartis awaits a final FDA ruling on its CAR-T therapy, Santa Monica, California-based Kite Pharma has jumped the Atlantic to file the first Marketing Authorization Application (MAA) with the European Medicines Agency (EMA).
Announced M... |
| - | Biotech partnered with NCI rounds up $20M to advance cancer immunotherapies into the clinic | Boosted by a partnership with the National Cancer Institute and $20 million in new funding, a California biotech startup is advancing new personalized immunotherapies for cancer.
Kite Pharma Inc. disclosed in a SEC filing this week that it ... |
| - | Kite Pharma to expand manufacturing capacity with Maryland plant | The maker of one of the two approved CAR-T cell therapies appears to be anticipating future demand with plans to open a new manufacturing plant.
Kite Pharma, the maker of Yescarta (axicabtagene ciloleucel) that Foster City, California-based... |
| - | 🚀 SpaceX gears up for another stellar year, active raises, and more
🤝 Venture Deals
📅 LA Tech Calendar
📙 What We’re Reading
🤝 Venture Deals | Happy Friday Los Angeles! You made it through the first week of 2024!🔦 Spotlight
Elon Musk may be a divisive (albeit entertaining) figure, but the continued success of SpaceX is pivotal for the aerospace industry in Los Angeles and more bro... |
| - | Venture Waves, Climate Tech Wins, and Silicon Beach's Ongoing Evolution
🤝 Venture Deals
🤝 Venture Deals
📅 LA Tech Calendar
📙 What We’re Reading | Anduril Seeks $1.5B in VC Funds
Defense company Anduril Industries Inc., based in Costa Mesa and founded by Palmer Luckey, is seeking to raise $1.5 billion in fresh funds to boost its valuation to $12.5 billion or more, according to sources... |
